The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial evaluating a 12-week regimen of interdigitating FOLFOX chemotherapy plus pelvic chemoradiation for the simultaneous treatment of primary and metastatic rectal cancer.
Michael Michael
No relevant relationships to disclose
Joseph James McKendrick
No relevant relationships to disclose
Mathias Bressel
No relevant relationships to disclose
Trevor Leong
No relevant relationships to disclose
Prasad Cooray
No relevant relationships to disclose
Alexander Graham Heriot
No relevant relationships to disclose
Malcolme Steel
No relevant relationships to disclose
Sarat Chander
No relevant relationships to disclose
Bev McClure
No relevant relationships to disclose
Sam Ngan
No relevant relationships to disclose